ADGRL4 and ovarian carcinoma: Systemic vascular ADGRL4/ELTD1 silencing in mice implanted with human tumour xenografts (colorectal and ovarian cancers) decreased microvascular density and induced tumour shrinkage with increased survival without a detrimental systemic vascular effect4.